We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Given safety risks and weaker evidence in some patients, the FDA says it is questioning whether positive findings reported for Teva’s asthma drug reslizumab are enough to warrant approval. Read More
The Department of Justice has netted $96 million from the pharmaceutical industry in settlements and judgments from civil cases involving fraud and false claims against the government in the fiscal year ending Sept. 30. Read More
Following a safety review, the FDA has added additional warnings to the labels of SGLT2 inhibitors for diabetes because they can cause the body to produce too much acid in the blood or lead to serious urinary tract infections. Read More
Teva Pharmaceuticals is getting ready to divest assets in anticipation of regulatory objections to its purchase of Allergan’s generics division, according to a corporate filing. Read More
Amid increased scrutiny over drug pricing, Mylan has been hit with a subpoena from the antitrust division of the Department of Justice over pricing of its 50-year-old antibiotic doxycycline, the drugmaker revealed in an SEC filing. Read More